Back to Search
Start Over
Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
- Source :
- Креативная хирургия и онкология, Vol 11, Iss 1, Pp 68-75 (2021)
- Publication Year :
- 2021
- Publisher :
- Bashkir State Medical University, 2021.
-
Abstract
- Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.
- Subjects :
- 0301 basic medicine
nf-kappa b
RD1-811
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
General Medicine
dhmeq
prostate cancer
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
ovarian cancer
breast cancer
030220 oncology & carcinogenesis
Medicine
Surgery
business
dehydroxymethylepoxyquinomycin
antitumour activity
carcinogenesis
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20763093 and 23070501
- Volume :
- 11
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Креативная хирургия и онкология
- Accession number :
- edsair.doi.dedup.....ee2540810b6a5b4f7293ec47462a093e